High Q Technologies Expands Quantum Protein Analysis Platform For Alzheimer's Drug Discovery
Ontario-based startup High Q Technologies is utilizing quantum sensing to improve protein analysis for Alzheimer's drug discovery. Their platform, Fathom, tracks protein movement to help researchers better understand how drugs interact with biological structures.
Why it matters
Advancements in quantum sensing could significantly accelerate the development of treatments for neurodegenerative diseases by providing more accurate data on protein dynamics.
An Ontario startup is deploying quantum sensing technology to help pharmaceutical researchers better understand how proteins move, something the company says could shorten drug discovery timelines for Alzheimer’s disease and other neurodegenerative disorders.
High Q Technologies has developed a quantum-enabled electron paramagnetic resonance (EPR) spectroscopy platform called Fathom that measures the motion of proteins in greater detail than many conventional structural biology techniques, according to medical news site MedPath . The company said the approach could help researchers identify and evaluate drug candidates more efficiently by providing a more complete picture of how proteins change shape as they interact with potential therapies.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in